Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging could help surgeons 'Feel' kidney tumors before cutting

NCT ID NCT06525831

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether special MRI and CT scans can accurately measure the stiffness of kidney tumors. Researchers will compare these scans to standard methods in 50 adults scheduled for kidney tumor surgery. The goal is to improve 3D-printed models that help surgeons plan operations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give surgeons a better way to see tumor stiffness before surgery, leading to more accurate 3D models and potentially better surgical planning.
What could go wrong
This is a small, early feasibility study (50 people) focused on imaging, not treatment. It may not lead to any direct patient benefit or change in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥ 18 years of age) * Scheduled for surgical management with nephrectomy for kidney tumor in the urology department of Bordeaux University Hospital * CT scan available or scheduled for surgery * Consent expressed for integration of the UroCCR database * Expressed consent for participation in the Rein 3D Print Mechanics study * Patients affiliated or benefiting from social security system Exclusion Criteria: * \- Pregnant or breast-feeding women * Contraindication to MRI (Magnetic Resonance Imaging) * Contraindication to injection of gadoline contrast agents * Biopsy performed within 15 days prior to MRI, CT and ultrasound scans (risk of artifactual alteration, via iatrogenic hemorrhagic changes, of the biomechanical properties of the renal tumor and parenchyma). * Presence of thoracolumbar arthrodesis material * Obese patient (body mass index ≥ 30 kg/m²) * Cystic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm * Necrotic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) \< 2 cm * Ascites * Person under legal protection * Difficulty understanding and expressing in French

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.